Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Enhances Dope Management And ADR Systems

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China will forbid pharmaceutical and chemical companies in China from manufacturing, selling, trading, exporting and importing any anabolic agents without the government approval, and China's State FDA will improve the adverse drug reaction report system, SFDA said at a July 8 press conference
Advertisement

Related Content

Opportunities Outweigh Challenges For Postmarketing Studies – BMS Exec
Opportunities Outweigh Challenges For Postmarketing Studies – BMS Exec
China Implements Credit Ratings System for Drug Advertising
China Implements Credit Ratings System for Drug Advertising
SFDA To Confirm Registrations For All Injectable Drugs
Advertisement
UsernamePublicRestriction

Register

SC069032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel